NCT00765063 - The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Diabetic Foot Ulcer

Interventions

DRUG

Fragmin

Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium

Trial Locations (27)

3103

Pfizer Investigational Site, Tønsberg

6043

Pfizer Investigational Site, Ransart

8000

Pfizer Investigational Site, Aarhus C

15127

Pfizer Investigational Site, Melissia/Athens

50139

Pfizer Investigational Site, Florence

61002

Pfizer Investigational Site, Kharkiv

76307

Pfizer Investigational Site, Karlsbad

79010

Pfizer Investigational Site, Lviv

119034

Pfizer Investigational Site, Moscow

123423

Pfizer Investigational Site, Moscow

127486

Pfizer Investigational Site, Moscow

194156

Pfizer Investigational Site, Saint Petersburg

A-1090

Pfizer Investigational Site, Vienna

R3A 1R9

Pfizer Investigational Site, Winnipeg

150 06

Pfizer Investigational Site, Prague

760 01

Pfizer Investigational Site, Zlín

90-153

Pfizer Investigational Site, Lodz

24-100

Pfizer Investigational Site, Puławy

02-097

Pfizer Investigational Site, Warsaw

51-124

Pfizer Investigational Site, Wroclaw

651 85

Pfizer Investigational Site, Karlstad

205 02

Pfizer Investigational Site, Malmo

118 83

Pfizer Investigational Site, Stockholm

171 76

Pfizer Investigational Site, Stockholm

182 88

Pfizer Investigational Site, Stockholm

02091

Pfizer Investigational Site, Kyiv

B9 5SS

Pfizer Investigational Site, Birmingham